Clinical Trial Update: Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

CRC01 is being evaluated in a Phase 1/2 clinical trial for severe refractory systemic lupus erythematosus, including lupus nephritis, with the study currently n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• CRC01

Snippet

Sponsor: Curocell Inc. | Conditions: Lupus Nephritis, Lupus Nephritis (LN) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING